The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Neoplasma (Bratislava)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 18237248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients.

  2007cited by this paper
• Serum HER-2 concentration in patients with primary breast cancer

  2006cited by this paper
• Prognostic significance of serum c-erbB-2 protein in breast cancer patients

  2005cited by this paper
• A Haplotype Analysis of HER-2 Gene Polymorphisms: Association with Breast Cancer Risk, HER-2 Protein Expression in the Tumor, and Disease Recurrence in Korea

  2005cited by this paper
• The influence of HER2 genotypes as molecular markers in ovarian cancer outcome.

  2005cited by this paper
• Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients.

  2004cited by this paper
• HER2 polymorphism and breast cancer risk in Portugal

  2004cited by this paper
• Targeted Therapy in Breast Cancer

  2004cited by this paper
• Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women.

  2004cited by this paper
• Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.

  2004cited by this paper
• Signal transduction and oncogenesis by ErbB/HER receptors.

  2004cited by this paper
• Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.

  2003cited by this paper
• HER2 Codon 655 Polymorphism and Risk of Breast Cancer in African Americans and Whites

  2003cited by this paper
• Interobserver Interpretative Reproducibility of GOLDFISH, A First Generation Gold-Facilitated Autometallographic Bright Field In Situ Hybridization Assay for HER-2/neu Amplification in Invasive Mammary Carcinoma

  2002cited by this paper
• A putative molecular-activation switch in the transmembrane domain of erbB2

  2002cited by this paper
• HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment.

  2002cited by this paper
• Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer

  2002cited by this paper
• C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment.

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

  2000cited by this paper
• Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Combined measurement of the c‐erbb‐2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse

  2000cited by this paper
• Serum c-erB-2 levels in monitoring of operable breast cancer patients.

  1999cited by this paper
• c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value

  1998cited by this paper
• Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

  1996cited by this paper
• Contribution of hydrophobic residues to the stability of human lysozyme: calorimetric studies and X-ray structural analysis of the five isoleucine to valine mutants.

  1996cited by this paper
• C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis.

  1996cited by this paper
• How cancer arises.

  1996cited by this paper
• Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer.

  1994cited by this paper
• Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.

  1992cited by this paper
• G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene.

  1991cited by this paper
• The molecular biology of breast cancer.

  1991cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Genomic Alterations in Human Breast Cancer: A Review

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

  1986cited by this paper
• The neu oncogene encodes an epidermal growth factor receptor-related protein

  1986cited by this paper
• Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

  1985cited by this paper
• Histological Grading and Prognosis in Breast Cancer

  1957cited by this paper

• Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis

  2020cites this paper
• The human epidermal growth factor receptor 2 (HER2) in the breast cancer : from measurement to targeted treatment

  2017cites this paper
• Association of polymorphisms in the 3 ’ UTR of ErbB 2 with the risk of hepatocellular carcinoma

  2016cites this paper
• Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors.

  2016cites this paper
• Study on extracellular matrix metalloproteinase inducer and human epidermal growth factor receptor-2 protein expression in papillary thyroid carcinoma using a quantum dot-based immunofluorescence technique

  2015cites this paper
• Coexpression of IL-6 and TNF-α: prognostic significance on breast cancer outcome.

  2014cites this paper
• Allellic HER-2 codon 655 polymorphism and the influence of plasma HER-2 levels in breast cancer Egyptian female patients

  2014cites this paper
• Polymorphisms in Genes of Drug Targets and Metabolism

  2014cites this paper
• Overall survival and clinicopathological characteristics of patients with breast cancer in relation to the expression pattern of HER-2, IL-6, TNF-α and TGF-β1.

  2013cites this paper
• ErbB2, EphrinB1, Src Kinase and PTPN13 Signaling Complex Regulates MAP Kinase Signaling in Human Cancers

  2012cites this paper
• Serum HER 2 Level in Epithelial Ovarian Cancer

  2010cites this paper
• Archive of SID Serum HER2 Level in Epithelial Ovarian Cancer

  2010cites this paper
• Serum HER2 Level in Epithelial Ovarian Cancer

  2010cites this paper
• Significance of Serum Tumor Necrosis Factor-Alpha and its Combination with Her-2 Codon 655 Polymorphism in the Diagnosis and Prognosis of Breast Cancer

  2010cites this paper
• EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma.

  2010cites this paper
• Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma

  2009cites this paper
• A comprehensive catalogue of functional genetic variations in the EGFR pathway: Protein–protein interaction analysis reveals novel genes and polymorphisms important for cancer research

  2009cites this paper
• The Val allele of HER-2 codon 655 predicts the progression of oral squamous cell carcinoma.

  2009cites this paper